Werewolf Therapeutics (HOWL) Stock: Buy, Sell, or Hold?
HOWL - Werewolf Therapeutics, Inc. Common Stock
$1.03
0.00 (0.00%)
▲
5d:
+3.31%
30d:
+4.1%
90d:
+141.22%
WAIT
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 03, 2026
11d
Get Alerted When HOWL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: HOWL shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: HOWL shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: HOWL is currently trading at $1.03, which is considered extended relative to its 30-day fair value range of $0.92 to $1.01.
Technical Outlook: Technically, HOWL is in a strong uptrend. Immediate support is located at $0.91, while resistance sits at $1.09.
Market Sentiment: HOWL scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $7.00 (+579.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, HOWL is in a strong uptrend. Immediate support is located at $0.91, while resistance sits at $1.09.
Market Sentiment: HOWL scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $7.00 (+579.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.92 -
$1.01
Company Quality Score
36/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
41.7%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 579.6% below Wall St target ($7.00)
- WARNING: Composite score 36/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.92 -
$1.01
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$0.17
(16.9%)
Support & Resistance Levels
Support Level
$0.91
Resistance Level
$1.09
Current Trend
Strong Uptrend
Technical data as of
Oct 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.75
Wall Street Target
$7.00
(+579.6%)
Revenue Growth (YoY)
-100.0%
Profit Margin
-164.8%
Share & Embed Analysis
Last updated: October 22, 2026 12:05 PM ET
Data refreshes hourly during market hours. Next update: 1:05 PM
Data refreshes hourly during market hours. Next update: 1:05 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HOWL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
STRONG BUY
32 analysts |
$571 | 49 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$369 | 50 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
27 analysts |
$436 | 39 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
21 analysts |
$307 | 51 HOLD |
|
RYTM
Rhythm Pharmaceuticals I… |
STRONG BUY
18 analysts |
$144 | 70 BUY |
